Phase 1/2 study of cyclin-dependent kinase (CDK)4/6 inhibitor palbociclib (PD-0332991) with bortezomib and dexamethasone in relapsed/refractory multiple myeloma

Ruben Niesvizky, Ashraf Z. Badros, Luciano J. Costa, Scott A. Ely, Seema B. Singhal, Edward A. Stadtmauer, Nisreen A. Haideri, Abdulraheem Yacoub, Georg Hess, Suzanne Lentzsch, Ivan Spicka, Asher A Chanan Khan, Marc S. Raab, Stefano Tarantolo, Ravi Vij, Jeffrey A. Zonder, Xiangao Huang, David Jayabalan, Maurizio Di Liberto, Xin HuangYuqiu Jiang, Sindy T. Kim, Sophia Randolph, Selina Chen-Kiang

Research output: Contribution to journalArticle

34 Citations (Scopus)

Abstract

This phase 1/2 study was the first to evaluate the safety and efficacy of the cyclin-dependent kinase (CDK) 4/6-specific inhibitor palbociclib (PD-0332991) in sequential combination with bortezomib and dexamethasone in relapsed/refractory multiple myeloma. The recommended phase 2 dose was palbociclib 100 mg orally once daily on days 1-12 of a 21-day cycle with bortezomib 1.0 mg/m2 (intravenous) and dexamethasone 20 mg (orally 30 min pre-bortezomib dosing) on days 8 and 11 (early G1 arrest) and days 15 and 18 (cell cycle resumed). Dose-limiting toxicities were primarily cytopenias; most other treatment-related adverse events were grade ≤ 3. At a bortezomib dose lower than that in other combination therapy studies, antitumor activity was observed (phase 1). In phase 2, objective responses were achieved in 5 (20%) patients; 11 (44%) achieved stable disease. Biomarker and pharmacodynamic assessments demonstrated that palbociclib inhibited CDK4/6 and the cell cycle initially in most patients.

Original languageEnglish (US)
Pages (from-to)3320-3328
Number of pages9
JournalLeukemia and Lymphoma
Volume56
Issue number12
DOIs
StatePublished - Dec 2 2015

Fingerprint

Cyclin-Dependent Kinase 6
Cyclin-Dependent Kinase 4
Multiple Myeloma
Dexamethasone
Cell Cycle
Biomarkers
Safety
Bortezomib
palbociclib
Therapeutics

Keywords

  • CDK 4/6
  • Cell cycle
  • cyclin-dependent kinase 4/6
  • multiple myeloma
  • palbociclib

ASJC Scopus subject areas

  • Hematology
  • Oncology
  • Cancer Research

Cite this

Phase 1/2 study of cyclin-dependent kinase (CDK)4/6 inhibitor palbociclib (PD-0332991) with bortezomib and dexamethasone in relapsed/refractory multiple myeloma. / Niesvizky, Ruben; Badros, Ashraf Z.; Costa, Luciano J.; Ely, Scott A.; Singhal, Seema B.; Stadtmauer, Edward A.; Haideri, Nisreen A.; Yacoub, Abdulraheem; Hess, Georg; Lentzsch, Suzanne; Spicka, Ivan; Chanan Khan, Asher A; Raab, Marc S.; Tarantolo, Stefano; Vij, Ravi; Zonder, Jeffrey A.; Huang, Xiangao; Jayabalan, David; Di Liberto, Maurizio; Huang, Xin; Jiang, Yuqiu; Kim, Sindy T.; Randolph, Sophia; Chen-Kiang, Selina.

In: Leukemia and Lymphoma, Vol. 56, No. 12, 02.12.2015, p. 3320-3328.

Research output: Contribution to journalArticle

Niesvizky, R, Badros, AZ, Costa, LJ, Ely, SA, Singhal, SB, Stadtmauer, EA, Haideri, NA, Yacoub, A, Hess, G, Lentzsch, S, Spicka, I, Chanan Khan, AA, Raab, MS, Tarantolo, S, Vij, R, Zonder, JA, Huang, X, Jayabalan, D, Di Liberto, M, Huang, X, Jiang, Y, Kim, ST, Randolph, S & Chen-Kiang, S 2015, 'Phase 1/2 study of cyclin-dependent kinase (CDK)4/6 inhibitor palbociclib (PD-0332991) with bortezomib and dexamethasone in relapsed/refractory multiple myeloma', Leukemia and Lymphoma, vol. 56, no. 12, pp. 3320-3328. https://doi.org/10.3109/10428194.2015.1030641
Niesvizky, Ruben ; Badros, Ashraf Z. ; Costa, Luciano J. ; Ely, Scott A. ; Singhal, Seema B. ; Stadtmauer, Edward A. ; Haideri, Nisreen A. ; Yacoub, Abdulraheem ; Hess, Georg ; Lentzsch, Suzanne ; Spicka, Ivan ; Chanan Khan, Asher A ; Raab, Marc S. ; Tarantolo, Stefano ; Vij, Ravi ; Zonder, Jeffrey A. ; Huang, Xiangao ; Jayabalan, David ; Di Liberto, Maurizio ; Huang, Xin ; Jiang, Yuqiu ; Kim, Sindy T. ; Randolph, Sophia ; Chen-Kiang, Selina. / Phase 1/2 study of cyclin-dependent kinase (CDK)4/6 inhibitor palbociclib (PD-0332991) with bortezomib and dexamethasone in relapsed/refractory multiple myeloma. In: Leukemia and Lymphoma. 2015 ; Vol. 56, No. 12. pp. 3320-3328.
@article{764e55d17c91483f99c7c397c32ab769,
title = "Phase 1/2 study of cyclin-dependent kinase (CDK)4/6 inhibitor palbociclib (PD-0332991) with bortezomib and dexamethasone in relapsed/refractory multiple myeloma",
abstract = "This phase 1/2 study was the first to evaluate the safety and efficacy of the cyclin-dependent kinase (CDK) 4/6-specific inhibitor palbociclib (PD-0332991) in sequential combination with bortezomib and dexamethasone in relapsed/refractory multiple myeloma. The recommended phase 2 dose was palbociclib 100 mg orally once daily on days 1-12 of a 21-day cycle with bortezomib 1.0 mg/m2 (intravenous) and dexamethasone 20 mg (orally 30 min pre-bortezomib dosing) on days 8 and 11 (early G1 arrest) and days 15 and 18 (cell cycle resumed). Dose-limiting toxicities were primarily cytopenias; most other treatment-related adverse events were grade ≤ 3. At a bortezomib dose lower than that in other combination therapy studies, antitumor activity was observed (phase 1). In phase 2, objective responses were achieved in 5 (20{\%}) patients; 11 (44{\%}) achieved stable disease. Biomarker and pharmacodynamic assessments demonstrated that palbociclib inhibited CDK4/6 and the cell cycle initially in most patients.",
keywords = "CDK 4/6, Cell cycle, cyclin-dependent kinase 4/6, multiple myeloma, palbociclib",
author = "Ruben Niesvizky and Badros, {Ashraf Z.} and Costa, {Luciano J.} and Ely, {Scott A.} and Singhal, {Seema B.} and Stadtmauer, {Edward A.} and Haideri, {Nisreen A.} and Abdulraheem Yacoub and Georg Hess and Suzanne Lentzsch and Ivan Spicka and {Chanan Khan}, {Asher A} and Raab, {Marc S.} and Stefano Tarantolo and Ravi Vij and Zonder, {Jeffrey A.} and Xiangao Huang and David Jayabalan and {Di Liberto}, Maurizio and Xin Huang and Yuqiu Jiang and Kim, {Sindy T.} and Sophia Randolph and Selina Chen-Kiang",
year = "2015",
month = "12",
day = "2",
doi = "10.3109/10428194.2015.1030641",
language = "English (US)",
volume = "56",
pages = "3320--3328",
journal = "Leukemia and Lymphoma",
issn = "1042-8194",
publisher = "Informa Healthcare",
number = "12",

}

TY - JOUR

T1 - Phase 1/2 study of cyclin-dependent kinase (CDK)4/6 inhibitor palbociclib (PD-0332991) with bortezomib and dexamethasone in relapsed/refractory multiple myeloma

AU - Niesvizky, Ruben

AU - Badros, Ashraf Z.

AU - Costa, Luciano J.

AU - Ely, Scott A.

AU - Singhal, Seema B.

AU - Stadtmauer, Edward A.

AU - Haideri, Nisreen A.

AU - Yacoub, Abdulraheem

AU - Hess, Georg

AU - Lentzsch, Suzanne

AU - Spicka, Ivan

AU - Chanan Khan, Asher A

AU - Raab, Marc S.

AU - Tarantolo, Stefano

AU - Vij, Ravi

AU - Zonder, Jeffrey A.

AU - Huang, Xiangao

AU - Jayabalan, David

AU - Di Liberto, Maurizio

AU - Huang, Xin

AU - Jiang, Yuqiu

AU - Kim, Sindy T.

AU - Randolph, Sophia

AU - Chen-Kiang, Selina

PY - 2015/12/2

Y1 - 2015/12/2

N2 - This phase 1/2 study was the first to evaluate the safety and efficacy of the cyclin-dependent kinase (CDK) 4/6-specific inhibitor palbociclib (PD-0332991) in sequential combination with bortezomib and dexamethasone in relapsed/refractory multiple myeloma. The recommended phase 2 dose was palbociclib 100 mg orally once daily on days 1-12 of a 21-day cycle with bortezomib 1.0 mg/m2 (intravenous) and dexamethasone 20 mg (orally 30 min pre-bortezomib dosing) on days 8 and 11 (early G1 arrest) and days 15 and 18 (cell cycle resumed). Dose-limiting toxicities were primarily cytopenias; most other treatment-related adverse events were grade ≤ 3. At a bortezomib dose lower than that in other combination therapy studies, antitumor activity was observed (phase 1). In phase 2, objective responses were achieved in 5 (20%) patients; 11 (44%) achieved stable disease. Biomarker and pharmacodynamic assessments demonstrated that palbociclib inhibited CDK4/6 and the cell cycle initially in most patients.

AB - This phase 1/2 study was the first to evaluate the safety and efficacy of the cyclin-dependent kinase (CDK) 4/6-specific inhibitor palbociclib (PD-0332991) in sequential combination with bortezomib and dexamethasone in relapsed/refractory multiple myeloma. The recommended phase 2 dose was palbociclib 100 mg orally once daily on days 1-12 of a 21-day cycle with bortezomib 1.0 mg/m2 (intravenous) and dexamethasone 20 mg (orally 30 min pre-bortezomib dosing) on days 8 and 11 (early G1 arrest) and days 15 and 18 (cell cycle resumed). Dose-limiting toxicities were primarily cytopenias; most other treatment-related adverse events were grade ≤ 3. At a bortezomib dose lower than that in other combination therapy studies, antitumor activity was observed (phase 1). In phase 2, objective responses were achieved in 5 (20%) patients; 11 (44%) achieved stable disease. Biomarker and pharmacodynamic assessments demonstrated that palbociclib inhibited CDK4/6 and the cell cycle initially in most patients.

KW - CDK 4/6

KW - Cell cycle

KW - cyclin-dependent kinase 4/6

KW - multiple myeloma

KW - palbociclib

UR - http://www.scopus.com/inward/record.url?scp=84948704253&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84948704253&partnerID=8YFLogxK

U2 - 10.3109/10428194.2015.1030641

DO - 10.3109/10428194.2015.1030641

M3 - Article

C2 - 25813205

AN - SCOPUS:84948704253

VL - 56

SP - 3320

EP - 3328

JO - Leukemia and Lymphoma

JF - Leukemia and Lymphoma

SN - 1042-8194

IS - 12

ER -